  COVID-19 has fast-paced drug re-positioning for its treatment. This work
builds computational models for the same. The aim is to assist clinicians with
a tool for selecting prospective antiviral treatments. Since the virus is known
to mutate fast, the tool is likely to help clinicians in selecting the right
set of antivirals for the mutated isolate.
  The main contribution of this work is a manually curated database publicly
shared, comprising of existing associations between viruses and their
corresponding antivirals. The database gathers similarity information using the
chemical structure of drugs and the genomic structure of viruses. Along with
this database, we make available a set of state-of-the-art computational drug
re-positioning tools based on matrix completion. The tools are first analysed
on a standard set of experimental protocols for drug target interactions. The
best performing ones are applied for the task of re-positioning antivirals for
COVID-19. These tools select six drugs out of which four are currently under
various stages of trial, namely Remdesivir (as a cure), Ribavarin (in
combination with others for cure), Umifenovir (as a prophylactic and cure) and
Sofosbuvir (as a cure). Another unanimous prediction is Tenofovir alafenamide,
which is a novel tenofovir prodrug developed in order to improve renal safety
when compared to the counterpart tenofovir disoproxil. Both are under trail,
the former as a cure and the latter as a prophylactic. These results establish
that the computational methods are in sync with the state-of-practice. We also
demonstrate how the selected drugs change as the SARS-Cov-2 mutates over time,
suggesting the importance of such a tool in drug prediction.
  The dataset and software is available publicly at
https://github.com/aanchalMongia/DVA and the prediction tool with a
user-friendly interface is available at http://dva.salsa.iiitd.edu.in.
